TMHC Shorts Retreat as Berkshire Deal Anchors the Price

Taylor Morrison Home Corporation is settling into a narrow trading range defined by a pending acquisition, a cooling short base, and a Street consensus that has run out of bullish arguments — all at once.

The positioning picture has shifted notably since last week's downgrade wave. Short interest has fallen 6.3% over the past week to 5.4% of the free float, continuing a gradual unwind that has taken the short base down from roughly 5.7 million shares at the start of June. The borrow market remains extraordinarily loose — availability is running at over 3,300% of short interest, meaning there are more than 33 shares available to borrow for every one currently shorted. Cost to borrow has crept up 32% on the week to 0.42%, but from such a low base that it remains well within the "easy borrow" range. The options market paints a slightly more cautious picture: the put/call ratio is at 0.85, about 1.3 standard deviations above its 20-day average of 0.64, a reading that has been building steadily through the first two weeks of June after a sharp flip from the more call-heavy positioning seen through late May. Together, the data describes a market where shorts are fading their positions while options traders hedge a little more carefully — not fear, but not conviction either.

The Street angle is now shaped entirely by the Berkshire Hathaway acquisition at $72.50 per share. Wolfe Research added a fourth downgrade this week, cutting to Peer Perform on June 10 — following RBC, Truist, and Citizens, who all stepped down between June 1 and June 2. The consensus has landed at Hold with a mean price target of $66.08, but that figure is mechanically distorted: it sits below the deal price, reflecting stale inputs from analysts who lowered targets before the acquisition announcement rather than any genuine bearishness on valuation. The stock itself closed at $71.64, essentially trading on deal-spread logic. The ORTEX EV/EBITDA multiple sits around 10.2x and price-to-book is at 1.0x — both roughly in line with the 1.3x P/TBV the Berkshire deal implies, which is already above the company's historical post-IPO average. Factor scores add little directional texture: EPS surprise ranks in the 79th percentile, a sign of solid recent execution, but the analyst recommendation differential scores at just the 1st percentile — a direct reflection of the downgrade pile-on.

The peer group is diverging from TMHC in a way worth noting. Close homebuilder peers MTH, CCS, and MHO all put in weekly gains of between 4% and 7%, suggesting the broader sector saw a constructive week while TMHC barely moved — up 0.2% on the day and 0.2% on the week. That lag is almost certainly acquisition-related compression: the deal price creates a hard ceiling that prevents TMHC from participating in any sector re-rating, while simultaneously providing a floor that keeps sellers at bay. The result is a stock that has essentially stopped trading on its own fundamentals.

Earnings are scheduled for July 22. The two most recent prints produced a 0.9% next-day gain and a 3.4% next-day loss respectively, with five-day moves of +2.2% and -4.0% — a modest reaction profile that reflects how thoroughly the deal narrative has displaced any earnings-driven price discovery. The July print will matter mainly for its read-through on deal timing rather than the underlying business metrics.

What to watch is the spread between the current price and the $72.50 deal price — currently around 120 basis points — and whether the cadence of further analyst resets or any regulatory update on the Berkshire transaction narrows or widens that gap into the summer.